CA2367899A1 - Triazolopyrimidinol compounds and salts thereof - Google Patents
Triazolopyrimidinol compounds and salts thereof Download PDFInfo
- Publication number
- CA2367899A1 CA2367899A1 CA002367899A CA2367899A CA2367899A1 CA 2367899 A1 CA2367899 A1 CA 2367899A1 CA 002367899 A CA002367899 A CA 002367899A CA 2367899 A CA2367899 A CA 2367899A CA 2367899 A1 CA2367899 A1 CA 2367899A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- chlorophenoxy
- seizures
- ethyl
- active compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 71
- 150000003839 salts Chemical class 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 206010010904 Convulsion Diseases 0.000 claims abstract description 19
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 13
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 13
- 206010015037 epilepsy Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 6
- CJEBZUWYGIVECV-UHFFFAOYSA-N 7-[1-(4-chlorophenoxy)ethyl]-1h-[1,2,4]triazolo[1,5-a]pyrimidin-5-one Chemical compound C=1C(=O)N=C2N=CNN2C=1C(C)OC1=CC=C(Cl)C=C1 CJEBZUWYGIVECV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 239000004090 neuroprotective agent Substances 0.000 claims description 6
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 230000000926 neurological effect Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- -1 halo hydroxy, mercapto Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000006186 oral dosage form Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000001030 gas--liquid chromatography Methods 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- CNEJNIADMWNACL-UHFFFAOYSA-N 2-amino-6-[1-(4-chlorophenoxy)ethyl]-1h-pyrimidin-4-one Chemical compound C=1C(=O)N=C(N)NC=1C(C)OC1=CC=C(Cl)C=C1 CNEJNIADMWNACL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VCANXUAOGIFXHL-UHFFFAOYSA-N methyl 4-(4-chlorophenoxy)-3-oxopentanoate Chemical compound COC(=O)CC(=O)C(C)OC1=CC=C(Cl)C=C1 VCANXUAOGIFXHL-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- JWNBCQQQLMTPLP-UHFFFAOYSA-N 3-propoxypyrrolidine Chemical compound CCCOC1CCNC1 JWNBCQQQLMTPLP-UHFFFAOYSA-N 0.000 description 1
- FCEPUTGEUCVRRI-SECBINFHSA-N 7-[(1r)-1-(4-chlorophenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound O([C@H](C)C=1N2N=CN=C2N=CC=1)C1=CC=C(Cl)C=C1 FCEPUTGEUCVRRI-SECBINFHSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FUGZMSWFMVRHEK-UHFFFAOYSA-L disodium dodecyl sulfate benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1.CCCCCCCCCCCCOS([O-])(=O)=O FUGZMSWFMVRHEK-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- GETKJYYPYMWCKP-UHFFFAOYSA-N n'-[6-[1-(4-chlorophenoxy)ethyl]-4-oxo-1h-pyrimidin-2-yl]-n-hydroxymethanimidamide Chemical compound C=1C(=O)N=C(\N=C/NO)NC=1C(C)OC1=CC=C(Cl)C=C1 GETKJYYPYMWCKP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol an d pharmaceutically acceptable salts thereof in the form of individual enantiomers and mixtures thereof including the racemic mixture, pharmaceutic al formulations containing this compound and the use of this compound in the treatment of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain traum a, head injuries and haemorrhage, are described.
Description
TRIAZOLOPYRIMIDINOL COMPOUNDS AND SALTS THEREOF
This invention relates to 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of and enantiomers and pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke brain trauma, head injuries and haemorrhage.
Compounds of formula A
Rs O ~ R~
Ra N~N
R
N
R N
z in which R~ represents H or optionally substituted alkyl, alkoxy or alkanoyl;
R2 and R3 independently represent H or optionally substituted alkyl, alkoxy, alkanoyl, alkylthio, alkylsulphinyl or sulphonyl; R4 and R5 independently represent H, alkyl or together with the carbon atom to which they are attached represent optionally substituted cycloalkylidene; and R6, R7 and R$ independently represent H, halo hydroxy, mercapto, cyano or optionally substituted alkyl, alkanoyl, alkoxy, alkoxycarbonyl, carboxy, alkanoyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, sulphamoyl, carbamoyl, alkylcarbamoyl or alkanoylamino; processes for their preparation, and their use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, head injuries and haemorrhage are described in W095/10521 (Knoll AG). A process for preparing these compounds is disclosed in W098/07724 (Knoll AG).
This invention relates to 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of and enantiomers and pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing them, to processes for their preparation and to their use in the treatment of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke brain trauma, head injuries and haemorrhage.
Compounds of formula A
Rs O ~ R~
Ra N~N
R
N
R N
z in which R~ represents H or optionally substituted alkyl, alkoxy or alkanoyl;
R2 and R3 independently represent H or optionally substituted alkyl, alkoxy, alkanoyl, alkylthio, alkylsulphinyl or sulphonyl; R4 and R5 independently represent H, alkyl or together with the carbon atom to which they are attached represent optionally substituted cycloalkylidene; and R6, R7 and R$ independently represent H, halo hydroxy, mercapto, cyano or optionally substituted alkyl, alkanoyl, alkoxy, alkoxycarbonyl, carboxy, alkanoyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, sulphamoyl, carbamoyl, alkylcarbamoyl or alkanoylamino; processes for their preparation, and their use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, head injuries and haemorrhage are described in W095/10521 (Knoll AG). A process for preparing these compounds is disclosed in W098/07724 (Knoll AG).
One compound of particular interest in W095/10521 is (R)-7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidine. In metabolic studies a metabolite of this compound has been identified and surprisingly this metabolite is also active.
In particular the present invention provides isolated 7-[1-(4 chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of and pharmaceutically acceptable salts thereof in the form of individual enantiomers and mixtures thereof including the racemic mixture.
The term isolated is used to indicate that the compound of the invention is in pure form and is not present in a human or an animal either in a free form or in an associated form.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of may form salts with organic or inorganic acids or bases. Particularly suitable salts of the compound are formed with acids include for example, salts with inorganic acids (such as hydrochloric, hydrobromic, hydriodic, nitric, sulphuric and phosphoric acids), salts with organic acids (such as malefic, acetic, citric, fumaric, tartaric, succinic, benzoic, pamoic, palmitic, methylsulphuric and dodecanoic acids) and salts with acidic amino acids (such as glutamic acid). Preferred compounds of the invention are salts of the compound formed with bases for example the potassium salt , the sodium salt or a salt formed with a basic amino acid. Such salts are prepared by reacting the compound of the invention with a suitable acid or base in a conventional manner.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of or its salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of or its salts may also exist in the form of solvates, (such as hydrates) and the present invention includes each solvate and mixtures thereof. The degree of solution may be non-stoichiometric and is preferably in the range 0 to 3, for example a hemihydrate, a monohydrate or a dehydrate.
7-[1-(4-Chlorophenoxy)ethyl)-1,2,4-triazolo[1,5-a]pyrimidin-5-of contains a chiral centre and exists in different enantiomeric forms the (+) form and the (-) form.
The present invention includes each enantiomer and mixtures thereof.
The enantiomers may be obtained by methods known to those skilled in the art. Such methods typically include any of the following:
resolution via formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation;
formation of diastereoisomeric derivatives or complexes which may be separated (for example, by crystallisation, gas-liquid or liquid chromatography), followed by the liberation of the desired enantiomer from the separated derivative;
selective derivatisation of one enantiomer by reaction with an enantiomer-specific reagent (for example enzymatic esterification, oxidation or reduction), followed by separation of the modified and unmodified enantiomers;
use of gas-liquid or liquid chromatography in a chiral environment (for example on a chiral support such as silica with a bound chiral ligand, or in the presence of a chiral solvent);
asymmetric synthesis of a specific enantiomer using optically active reagents, substrates, catalysts, solvents or enzymatic processes; and asymmetric transformation of one enantiomer into the other.
It will be appreciated that where the active moiety is transformed by the separation procedures described above, a further step may be required to convert the transformation product back to the active moiety.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer and mixtures thereof.
In particular the present invention provides isolated 7-[1-(4 chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of and pharmaceutically acceptable salts thereof in the form of individual enantiomers and mixtures thereof including the racemic mixture.
The term isolated is used to indicate that the compound of the invention is in pure form and is not present in a human or an animal either in a free form or in an associated form.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of may form salts with organic or inorganic acids or bases. Particularly suitable salts of the compound are formed with acids include for example, salts with inorganic acids (such as hydrochloric, hydrobromic, hydriodic, nitric, sulphuric and phosphoric acids), salts with organic acids (such as malefic, acetic, citric, fumaric, tartaric, succinic, benzoic, pamoic, palmitic, methylsulphuric and dodecanoic acids) and salts with acidic amino acids (such as glutamic acid). Preferred compounds of the invention are salts of the compound formed with bases for example the potassium salt , the sodium salt or a salt formed with a basic amino acid. Such salts are prepared by reacting the compound of the invention with a suitable acid or base in a conventional manner.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of or its salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of or its salts may also exist in the form of solvates, (such as hydrates) and the present invention includes each solvate and mixtures thereof. The degree of solution may be non-stoichiometric and is preferably in the range 0 to 3, for example a hemihydrate, a monohydrate or a dehydrate.
7-[1-(4-Chlorophenoxy)ethyl)-1,2,4-triazolo[1,5-a]pyrimidin-5-of contains a chiral centre and exists in different enantiomeric forms the (+) form and the (-) form.
The present invention includes each enantiomer and mixtures thereof.
The enantiomers may be obtained by methods known to those skilled in the art. Such methods typically include any of the following:
resolution via formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation;
formation of diastereoisomeric derivatives or complexes which may be separated (for example, by crystallisation, gas-liquid or liquid chromatography), followed by the liberation of the desired enantiomer from the separated derivative;
selective derivatisation of one enantiomer by reaction with an enantiomer-specific reagent (for example enzymatic esterification, oxidation or reduction), followed by separation of the modified and unmodified enantiomers;
use of gas-liquid or liquid chromatography in a chiral environment (for example on a chiral support such as silica with a bound chiral ligand, or in the presence of a chiral solvent);
asymmetric synthesis of a specific enantiomer using optically active reagents, substrates, catalysts, solvents or enzymatic processes; and asymmetric transformation of one enantiomer into the other.
It will be appreciated that where the active moiety is transformed by the separation procedures described above, a further step may be required to convert the transformation product back to the active moiety.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer and mixtures thereof.
7-[1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of may exist in zwitterionic form and the present invention includes each zwitterionic form and mixtures thereof.
The present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4 triazolo[1,5-a]pyrimidin-5-of together with a pharmaceutically acceptable diluent or carrier. Such pharmaceutical compositions may be used for the treatment of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke.
As used hereinafter, the term "active compound" denotes isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol. In therapeutic use, the active compound may be administered orally, rectally or parenterally. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for such methods of administration. The compositions may be formulated in a manner known to those skilled in the art, to give a controlled release, for example rapid release or sustained release, of the active compound. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions may contain from about 0.1 % to about 99% by weight of active compound and are generally prepared in unit dosage form. Preferably the unit dosage of active ingredient is from about 1 mg to about 500 mg. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.
Preferably the compositions of the invention are administered orally in the known pharmaceutical forms for such administration. Dosage forms suitable for oral administration may comprise tablets, pills, capsules, caplets, multiparticulates including: granules, beads, pellets and micro-encapsulated particles; powders, elixirs, syrups, solutions and aqueous or oily suspensions.
Solid oral dosage forms, for example tablets, may be prepared by mixing the active compound with one or more of the following ingredients or mixtures thereof:
inert diluents, for example calcium carbonate, calcium sulphate, compressible sugar, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, microcrystalline 5 cellulose, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate disintegrating agents, for example alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate and starch; including maize starch and agar;
lubricating agents, for example calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate sodium lauryl sulphate, sodium stearyl fumarate, stearic acid, talc and zinc stearate;
binders, for example acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminium silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch including maize starch, zein, sugars (such as sucrose, molasses and lactose), and natural and synthetic gums (such as extract of Irish moss, polyethylene glycol, waxes, microcrystalline cellulose and polyvinylpyrrolidone);
colouring agents, for example conventional pharmaceutically acceptable dyes;
sweetening and flavouring agents;
preservatives;
one or more pharmaceutically acceptable couple or couples (such as those comprising an acid and a carbonate or bicarbonate salt), which effervesces to aid dissolution when the solid dosage form is added to water; and other optional ingredients known in the art to permit production of oral dosage forms by known methods such as tabletting.
The present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4 triazolo[1,5-a]pyrimidin-5-of together with a pharmaceutically acceptable diluent or carrier. Such pharmaceutical compositions may be used for the treatment of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke.
As used hereinafter, the term "active compound" denotes isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol. In therapeutic use, the active compound may be administered orally, rectally or parenterally. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for such methods of administration. The compositions may be formulated in a manner known to those skilled in the art, to give a controlled release, for example rapid release or sustained release, of the active compound. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions may contain from about 0.1 % to about 99% by weight of active compound and are generally prepared in unit dosage form. Preferably the unit dosage of active ingredient is from about 1 mg to about 500 mg. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.
Preferably the compositions of the invention are administered orally in the known pharmaceutical forms for such administration. Dosage forms suitable for oral administration may comprise tablets, pills, capsules, caplets, multiparticulates including: granules, beads, pellets and micro-encapsulated particles; powders, elixirs, syrups, solutions and aqueous or oily suspensions.
Solid oral dosage forms, for example tablets, may be prepared by mixing the active compound with one or more of the following ingredients or mixtures thereof:
inert diluents, for example calcium carbonate, calcium sulphate, compressible sugar, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, microcrystalline 5 cellulose, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate disintegrating agents, for example alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate and starch; including maize starch and agar;
lubricating agents, for example calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate sodium lauryl sulphate, sodium stearyl fumarate, stearic acid, talc and zinc stearate;
binders, for example acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminium silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch including maize starch, zein, sugars (such as sucrose, molasses and lactose), and natural and synthetic gums (such as extract of Irish moss, polyethylene glycol, waxes, microcrystalline cellulose and polyvinylpyrrolidone);
colouring agents, for example conventional pharmaceutically acceptable dyes;
sweetening and flavouring agents;
preservatives;
one or more pharmaceutically acceptable couple or couples (such as those comprising an acid and a carbonate or bicarbonate salt), which effervesces to aid dissolution when the solid dosage form is added to water; and other optional ingredients known in the art to permit production of oral dosage forms by known methods such as tabletting.
Solid oral dosage forms may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Film coated, solid oral dosage forms comprising compositions of the invention may be advantageous, depending on the nature of the active compound.
Various materials, for example shellac and/or sugar, may be present as coatings, or to otherwise modify the physical form of the oral dosage form. For example tablets or pills may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate and/or hydroxy propyl methylcellulose phthalate.
Capsules or caplets (for example hard or soft gelatin capsules) comprising the active compound (with or without added ~excipients such as a fatty oil), may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The contents of the capsule or caplet may be formulated using known methods to give sustained release of the active compound.
Liquid oral dosage forms comprising compositions of the invention may be an elixir, suspension or syrup, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent (such as sodium carboxymethylcellulose), or oily suspensions containing the active compound in a suitable vegetable oil (such as arachis oil or sunflower oil).
Liquid oral dosage forms may also comprise one or more sweetening agent, flavouring agent, preservatives and mixtures thereof.
The active compound may be formulated into granules or powders with or without additional excipients. The granules or powders may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules or powders may contain disintegrants (for example a pharmaceutically acceptable effervescent couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.
Preferably each of the above oral dosage forms may contain from about 1 mg to about 500 mg (for example 10 mg, 50 mg, 100 mg, 200 mg, or 400 mg) of the active compound.
Various materials, for example shellac and/or sugar, may be present as coatings, or to otherwise modify the physical form of the oral dosage form. For example tablets or pills may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate and/or hydroxy propyl methylcellulose phthalate.
Capsules or caplets (for example hard or soft gelatin capsules) comprising the active compound (with or without added ~excipients such as a fatty oil), may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The contents of the capsule or caplet may be formulated using known methods to give sustained release of the active compound.
Liquid oral dosage forms comprising compositions of the invention may be an elixir, suspension or syrup, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent (such as sodium carboxymethylcellulose), or oily suspensions containing the active compound in a suitable vegetable oil (such as arachis oil or sunflower oil).
Liquid oral dosage forms may also comprise one or more sweetening agent, flavouring agent, preservatives and mixtures thereof.
The active compound may be formulated into granules or powders with or without additional excipients. The granules or powders may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules or powders may contain disintegrants (for example a pharmaceutically acceptable effervescent couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.
Preferably each of the above oral dosage forms may contain from about 1 mg to about 500 mg (for example 10 mg, 50 mg, 100 mg, 200 mg, or 400 mg) of the active compound.
Compositions of the invention may be administered rectally in the known pharmaceutical forms for such administration, for example, suppositories with hard fat, semi-synthetic glyceride, cocoa butter or polyethylene glycol bases.
Compositions of the invention may also be administered parenterally, for example by intravenous injection, in the known pharmaceutical forms for such administration, for example sterile suspensions in aqueous or oily media, or sterile solutions in a suitable solvent.
The active compound may also be administered by continuous infusion either from an external source (for example by intravenous infusion) or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released (for example by osmosis) or implants. Implants may be liquid such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused (for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or ester). Implants may also be solid in the form of an implanted support (forexample a synthetic resin or waxy material) for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
In some formulations it may be beneficial to use the active compound, or pharmaceutical compositions containing them, in the form of particles of very small size, for example as obtained by fluid energy milling.
In the above compositions the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
Isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of is indicated for use as neuroprotective agents to protect against conditions such as stroke, and for the treatment of seizures and neurological disorders such as epilepsy.
Compositions of the invention may also be administered parenterally, for example by intravenous injection, in the known pharmaceutical forms for such administration, for example sterile suspensions in aqueous or oily media, or sterile solutions in a suitable solvent.
The active compound may also be administered by continuous infusion either from an external source (for example by intravenous infusion) or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released (for example by osmosis) or implants. Implants may be liquid such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused (for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or ester). Implants may also be solid in the form of an implanted support (forexample a synthetic resin or waxy material) for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
In some formulations it may be beneficial to use the active compound, or pharmaceutical compositions containing them, in the form of particles of very small size, for example as obtained by fluid energy milling.
In the above compositions the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
Isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of is indicated for use as neuroprotective agents to protect against conditions such as stroke, and for the treatment of seizures and neurological disorders such as epilepsy.
The therapeutic activity of the compound has been demonstrated by means of various in vivo pharmacological tests in standard laboratory animals. Such tests include those tests of convulsant activity in mice described below.
Accordingly, a further aspect of the present invention provides a method of treating seizures and/or neurological disorders such as epilepsy and/or a method of neuroprotection to protect against conditions such as stroke, in animals including human beings, which comprises the administration to a patient in need thereof a therapeutically effective amount of the active compound and/or a pharmaceutical composition or compositions containing a therapeutically effective amount of the active compound. Thus isolated 7-(1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of is useful for the inhibition of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings.
Whilst the precise amount of the active compound administered in the treatments outlined above will depend on a number of factors, for example the severity of the condition, the age and past medical history of the patient, and always lies within the sound discretion of the administering pharmacist, physician or veterinary a suitable daily dose of the active compound for administration to human beings, is generally from about 1 mg to about 5000 mg, more usually from about 5 mg to about 1000 mg, given in a single dose or in divided doses at one or more times during the day. Oral administration is preferred.
The active compounds may be used in adjunctive therapy with one or more other compound or compounds having activity in the treatment of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings. It will be appreciated that the term therapy as used herein includes prophylactic use of the active compound and pharmaceutical composition or compositions comprising a therapeutically effective amount of the active compound, for example to prevent the onset of neurological disorders such as epileptic seizures, or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings. The active compound and/or a pharmaceutical composition or compositions comprising a therapeutically effective amount of the active compound may be used to provide a local and/or systemic therapeutic effect.
A still further aspect of the present invention provides use of the active compound in the preparation of a medicament for the treatment of seizures and/or neurological disorders such as epilepsy and/or for neuroprotection to protect against conditions such as stroke, in animals including human beings.
Processes for the preparation of the above compound are part of the present invention. 7-[1-(4-Chlorophenoxy)ethylj-1,2,4-triazolo[1,5-ajpyrimidin-5-of may be prepared by cyclising a compound of formula II
O
CI
~ ~N NOH II
HO N"N"H
optionally in the presence of an acid. Preferably the process is carried out at a temperature in the range 0° -250°C, more preferably in the range 50° -150°C.
Preferably the acid is polyphosphoric acid.
The anticonvulsant activity of 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-ajpyrimidin-5-of was demonstrated by the following pharmacological test.
The anticonvulsant activity involved observing the ability of a test compound to inhibit seizures in mice induced by a maximal electroshock. Hereinafter, this test is referred to as 'MESM'.
In the MESM experiments, groups of male mice in the weight range 25 to 30 grammes had free access to food and water until the start of the experiment.
The mice were divided into two groups, a control group and a test group to which the test compound would be administered. The control group received an oral dose of 10 ml/kg of a vehicle of 1 % aqueous methyl cellulose solution. The test group received orally, suspended in the same dose of the methylcellulose vehicle, the test compound at a dose of either 100 mg/kg for initial testing or, if enough compound was available, at a range of doses to determine an ED5° (see below).
One hour after administration of all drugs an electroshock of duration 1.0 second was administered to all the mice in both groups through ear clip electrodes moistened with saline. The 5 electroshock had an intensity of 99 mA, frequency of 50 Hz and pulse width of 0.4 ms. Such a shock would generally be expected to induce a seizure in the mice.
During the following two minutes the mice in each group were observed, the number of mice in each group exhibiting tonic hind limb extension was recorded and 10 thus the percentage of mice in which seizures had been inhibited was determined.
The greater the anticonvulsant activity of the test compound, the higher was the percentage recorded in the MESM test.
If results at more than one dose were available, then a value for the dose inhibiting seizures in 50% of the mice (ED5°) was calculated from the regression straight line plot of the percentage of mice in which seizures were inhibited against the dose of the test compound administered.
7-(1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of was administered at a dose of 100 mg/kg 60 min before tests either by the intraperitoneal (i.p.) or oral (p.o.) route. The test compound increased significantly the threshold for maximal electroshock-induced seizures following both i.p. (77% increase) and p.o.
(22% increase) administration.
The invention will now be illustrated by the following non-limiting examples.
The final product of each example was characterised using one or more of the following techniques: elemental analysis; infra-red spectroscopy; nuclear magnetic resonance spectroscopy; gas-liquid chromatography; and liquid chromatography.
Temperatures are given in degrees Celsius.
Example 1 1 a) A mixture of 2-(4-chlorophenoxy)propionic acid (30.0 g) in toluene (300 ml) was added to a solution of thionyl chloride (22.0 ml) and dimethylformamide (2 ml) in toluene (150 ml) at 60-70°C with stirring. The mixture was stirred for 18 hours at 70-80°C and then evaporated under reduced pressure to give the acid chloride. A solution of Meldrum's acid (23.5 g) in dichloromethane (90 ml) was cooled to 0-5°C under nitrogen and pyridine (33 ml) was added at 0-5°C. To this mixture was added a solution of the acid chloride prepared above in dichloromethane (90 ml) dropwise keeping the temperature below 5°C. The mixture was stirred for 1 hour at 0-5°C and then at ambient temperature for 18 hours. The mixture was diluted with dichloromethane (150 ml) and washed with 2M hydrochloric acid (2 x 100 ml) and then with saturated sodium bicarbonate solution (100 ml) and then water (100 ml). The bicarbonate washes were acidified with 5M hydrochloric acid and extracted into dichloromethane (2 x 50 ml). These dichloromethane extracts were combined with the original dichloromethane solution and dried over magnesium sulphate and evaporated to give the crude intermediate Meldrum's acid derivative. This derivative was boiled under reflux with methanol (400 ml) and methanolic hydrogen chloride solution (10 ml) for 6 hours and then left to stand at ambient temperature for 66 hours. The mixture was evaporated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water (100 ml). The ethyl acetate layer was separated, washed with sodium bicarbonate solution (0.5M, 100 ml), brine and then dried over magnesium sulphate and evaporated under reduced pressure to give an oil which was distilled under high vacuum. The distillate was purified by flash column chromatography on silica gel using petroleum ether, b.p. 60-80°C / ethyl acetate 20:1 as the mobile phase to give methyl 4-(4-chlorophenoxy)-3-oxopentanoate as an oil.
b) Guanidine hydrochloride (1.87 g) was added with stirring to a solution of sodium (0.41 g) in ethanol (15 ml). The mixture was stirred for 15 minutes and then to this mixture was added a solution of methyl 4-(4-chlorophenoxy)-3-oxopentanoate (5.0 g) in ethanol (15 ml). The mixture was stirred and boiled under reflux for 16 hours. The mixture was cooled and then evaporated to dryness under reduced pressure to give a solid. The solid was triturated with water (10 ml) containing glacial acetic acid (2 ml) and dichloromethane (20 ml) for 1 hour and then filtered. The residue obtained was washed with water (20 ml) and then with dichloromethane (20 ml) and dried in vacuo to give 2-amino-4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidine, m.p. 125°C.
c) A mixture of 2-amino-4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidine (0.5 g), dimethylformamide dimethyl acetal (0.5 ml) and toluene (5 ml) was stirred and boiled under reflux for 8 hours. The mixture was allowed to stand at ambient temperature for 24 hours and then evaporated to dryness under reduced pressure to give a solid which was triturated with diethyl ether (2 x5ml) and filtered to give N-{4-[1-(4-Chlorophenoxy)ethyl]-6-hydroxypyrimidin-2-yl}-N'N'-dimethylformamidine, m.p. 190°C.
d) Sodium hydride (62 mg of a 60% dispersion in mineral oil from which the mineral oil had been removed by washing with petrol) was dissolved in methanol (10 ml) and hydroxylamine hydrochloride (0.12 g) was added. The mixture was stirred for 5 minutes and then theformamidine (0.5 g) obtained in c) was added. The mixture was stirred at ambient temperature for 72 hours and then evaporated under reduced pressure to give a residue which was washed with water (2 x 5m1) and dried in vacuo to give N-{4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidin-2-yl}formamide oxime, m.p.
120°C.
e) The product from d) (5.0 g) and polyphosphoric acid (100 g) were stirred and heated on a steam bath for 4 hours. The mixture was allowed to cool to ambient temperature and then ice (100 g) and ethyl acetate (100 ml) were added. A solution of potassium carbonate (110 g) in water (total volume 100 ml) was added dropwise over 15 minutes to neutralise the mixture. The mixture was separated and the aqueous layer was extracted with ethyl acetate (100m1). The combined ethyl acetate layers were dried over magnesium sulphate and evaporated under reduced pressure to give a solid which was purified by flash column chromatography on silica gel using dichloromethane / methanol (75:3) as the mobile phase to give 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol, m.p. 190°C.
Accordingly, a further aspect of the present invention provides a method of treating seizures and/or neurological disorders such as epilepsy and/or a method of neuroprotection to protect against conditions such as stroke, in animals including human beings, which comprises the administration to a patient in need thereof a therapeutically effective amount of the active compound and/or a pharmaceutical composition or compositions containing a therapeutically effective amount of the active compound. Thus isolated 7-(1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of is useful for the inhibition of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings.
Whilst the precise amount of the active compound administered in the treatments outlined above will depend on a number of factors, for example the severity of the condition, the age and past medical history of the patient, and always lies within the sound discretion of the administering pharmacist, physician or veterinary a suitable daily dose of the active compound for administration to human beings, is generally from about 1 mg to about 5000 mg, more usually from about 5 mg to about 1000 mg, given in a single dose or in divided doses at one or more times during the day. Oral administration is preferred.
The active compounds may be used in adjunctive therapy with one or more other compound or compounds having activity in the treatment of seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings. It will be appreciated that the term therapy as used herein includes prophylactic use of the active compound and pharmaceutical composition or compositions comprising a therapeutically effective amount of the active compound, for example to prevent the onset of neurological disorders such as epileptic seizures, or as neuroprotective agents to protect against conditions such as stroke, in animals including human beings. The active compound and/or a pharmaceutical composition or compositions comprising a therapeutically effective amount of the active compound may be used to provide a local and/or systemic therapeutic effect.
A still further aspect of the present invention provides use of the active compound in the preparation of a medicament for the treatment of seizures and/or neurological disorders such as epilepsy and/or for neuroprotection to protect against conditions such as stroke, in animals including human beings.
Processes for the preparation of the above compound are part of the present invention. 7-[1-(4-Chlorophenoxy)ethylj-1,2,4-triazolo[1,5-ajpyrimidin-5-of may be prepared by cyclising a compound of formula II
O
CI
~ ~N NOH II
HO N"N"H
optionally in the presence of an acid. Preferably the process is carried out at a temperature in the range 0° -250°C, more preferably in the range 50° -150°C.
Preferably the acid is polyphosphoric acid.
The anticonvulsant activity of 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-ajpyrimidin-5-of was demonstrated by the following pharmacological test.
The anticonvulsant activity involved observing the ability of a test compound to inhibit seizures in mice induced by a maximal electroshock. Hereinafter, this test is referred to as 'MESM'.
In the MESM experiments, groups of male mice in the weight range 25 to 30 grammes had free access to food and water until the start of the experiment.
The mice were divided into two groups, a control group and a test group to which the test compound would be administered. The control group received an oral dose of 10 ml/kg of a vehicle of 1 % aqueous methyl cellulose solution. The test group received orally, suspended in the same dose of the methylcellulose vehicle, the test compound at a dose of either 100 mg/kg for initial testing or, if enough compound was available, at a range of doses to determine an ED5° (see below).
One hour after administration of all drugs an electroshock of duration 1.0 second was administered to all the mice in both groups through ear clip electrodes moistened with saline. The 5 electroshock had an intensity of 99 mA, frequency of 50 Hz and pulse width of 0.4 ms. Such a shock would generally be expected to induce a seizure in the mice.
During the following two minutes the mice in each group were observed, the number of mice in each group exhibiting tonic hind limb extension was recorded and 10 thus the percentage of mice in which seizures had been inhibited was determined.
The greater the anticonvulsant activity of the test compound, the higher was the percentage recorded in the MESM test.
If results at more than one dose were available, then a value for the dose inhibiting seizures in 50% of the mice (ED5°) was calculated from the regression straight line plot of the percentage of mice in which seizures were inhibited against the dose of the test compound administered.
7-(1-(4-Chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-of was administered at a dose of 100 mg/kg 60 min before tests either by the intraperitoneal (i.p.) or oral (p.o.) route. The test compound increased significantly the threshold for maximal electroshock-induced seizures following both i.p. (77% increase) and p.o.
(22% increase) administration.
The invention will now be illustrated by the following non-limiting examples.
The final product of each example was characterised using one or more of the following techniques: elemental analysis; infra-red spectroscopy; nuclear magnetic resonance spectroscopy; gas-liquid chromatography; and liquid chromatography.
Temperatures are given in degrees Celsius.
Example 1 1 a) A mixture of 2-(4-chlorophenoxy)propionic acid (30.0 g) in toluene (300 ml) was added to a solution of thionyl chloride (22.0 ml) and dimethylformamide (2 ml) in toluene (150 ml) at 60-70°C with stirring. The mixture was stirred for 18 hours at 70-80°C and then evaporated under reduced pressure to give the acid chloride. A solution of Meldrum's acid (23.5 g) in dichloromethane (90 ml) was cooled to 0-5°C under nitrogen and pyridine (33 ml) was added at 0-5°C. To this mixture was added a solution of the acid chloride prepared above in dichloromethane (90 ml) dropwise keeping the temperature below 5°C. The mixture was stirred for 1 hour at 0-5°C and then at ambient temperature for 18 hours. The mixture was diluted with dichloromethane (150 ml) and washed with 2M hydrochloric acid (2 x 100 ml) and then with saturated sodium bicarbonate solution (100 ml) and then water (100 ml). The bicarbonate washes were acidified with 5M hydrochloric acid and extracted into dichloromethane (2 x 50 ml). These dichloromethane extracts were combined with the original dichloromethane solution and dried over magnesium sulphate and evaporated to give the crude intermediate Meldrum's acid derivative. This derivative was boiled under reflux with methanol (400 ml) and methanolic hydrogen chloride solution (10 ml) for 6 hours and then left to stand at ambient temperature for 66 hours. The mixture was evaporated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water (100 ml). The ethyl acetate layer was separated, washed with sodium bicarbonate solution (0.5M, 100 ml), brine and then dried over magnesium sulphate and evaporated under reduced pressure to give an oil which was distilled under high vacuum. The distillate was purified by flash column chromatography on silica gel using petroleum ether, b.p. 60-80°C / ethyl acetate 20:1 as the mobile phase to give methyl 4-(4-chlorophenoxy)-3-oxopentanoate as an oil.
b) Guanidine hydrochloride (1.87 g) was added with stirring to a solution of sodium (0.41 g) in ethanol (15 ml). The mixture was stirred for 15 minutes and then to this mixture was added a solution of methyl 4-(4-chlorophenoxy)-3-oxopentanoate (5.0 g) in ethanol (15 ml). The mixture was stirred and boiled under reflux for 16 hours. The mixture was cooled and then evaporated to dryness under reduced pressure to give a solid. The solid was triturated with water (10 ml) containing glacial acetic acid (2 ml) and dichloromethane (20 ml) for 1 hour and then filtered. The residue obtained was washed with water (20 ml) and then with dichloromethane (20 ml) and dried in vacuo to give 2-amino-4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidine, m.p. 125°C.
c) A mixture of 2-amino-4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidine (0.5 g), dimethylformamide dimethyl acetal (0.5 ml) and toluene (5 ml) was stirred and boiled under reflux for 8 hours. The mixture was allowed to stand at ambient temperature for 24 hours and then evaporated to dryness under reduced pressure to give a solid which was triturated with diethyl ether (2 x5ml) and filtered to give N-{4-[1-(4-Chlorophenoxy)ethyl]-6-hydroxypyrimidin-2-yl}-N'N'-dimethylformamidine, m.p. 190°C.
d) Sodium hydride (62 mg of a 60% dispersion in mineral oil from which the mineral oil had been removed by washing with petrol) was dissolved in methanol (10 ml) and hydroxylamine hydrochloride (0.12 g) was added. The mixture was stirred for 5 minutes and then theformamidine (0.5 g) obtained in c) was added. The mixture was stirred at ambient temperature for 72 hours and then evaporated under reduced pressure to give a residue which was washed with water (2 x 5m1) and dried in vacuo to give N-{4-[1-(4-chlorophenoxy)ethyl]-6-hydroxypyrimidin-2-yl}formamide oxime, m.p.
120°C.
e) The product from d) (5.0 g) and polyphosphoric acid (100 g) were stirred and heated on a steam bath for 4 hours. The mixture was allowed to cool to ambient temperature and then ice (100 g) and ethyl acetate (100 ml) were added. A solution of potassium carbonate (110 g) in water (total volume 100 ml) was added dropwise over 15 minutes to neutralise the mixture. The mixture was separated and the aqueous layer was extracted with ethyl acetate (100m1). The combined ethyl acetate layers were dried over magnesium sulphate and evaporated under reduced pressure to give a solid which was purified by flash column chromatography on silica gel using dichloromethane / methanol (75:3) as the mobile phase to give 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol, m.p. 190°C.
Example A
The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples.
a) Ca sules In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.
b) Tablets Tablets are prepared from the following ingredients.
Parts by weight Active compound 10 Lactose 190 Maize starch 22 Polyvinylpyrrolidone 10 Magnesium stearate 3 The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinyl-pyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in atabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.
The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples.
a) Ca sules In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.
b) Tablets Tablets are prepared from the following ingredients.
Parts by weight Active compound 10 Lactose 190 Maize starch 22 Polyvinylpyrrolidone 10 Magnesium stearate 3 The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinyl-pyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in atabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.
c) Enteric coated tablets Tablets are prepared by the method described in (b) above. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).
d) Suppositories In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
d) Suppositories In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
Claims (5)
1. Isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol and pharmaceutically acceptable salts thereof in the form of individual enantiomers and mixtures thereof including the racemic mixture.
2. Pharmaceutical compositions for the treatment of seizures and/or neurological disorders such as epilepsy, and/or for use as neuroprotective agents to protect against conditions such as stroke, comprising a therapeutically effective amount of a compound according to claim 1.
3. Use of a compound as claimed in claim 1 in the preparation of a medicament for the treatment of seizures and/or neurological disorders such as epilepsy, and/or for neuroprotection to protect against conditions such as stroke, in animals including human beings.
4.. A method of treating seizures and/or neurological disorders such as epilepsy and/or of neuroprotection to protect against conditions such as stroke, in animals including human beings, which comprises the administration of a therapeutically effective amount of a compound as claimed in claim 1.
5. A process for the preparation of the compound as claimed in claim 1 comprising cyclising a compound of formula II optionally in the presence of an acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9906124.4A GB9906124D0 (en) | 1999-03-18 | 1999-03-18 | Therapeutic agent |
GB9906124.4 | 1999-03-18 | ||
PCT/EP2000/001934 WO2000056733A1 (en) | 1999-03-18 | 2000-03-06 | Triazolopyrimidinol compounds and salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2367899A1 true CA2367899A1 (en) | 2000-09-28 |
Family
ID=10849797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002367899A Abandoned CA2367899A1 (en) | 1999-03-18 | 2000-03-06 | Triazolopyrimidinol compounds and salts thereof |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1183257A1 (en) |
JP (1) | JP2002540110A (en) |
CN (1) | CN1353714A (en) |
AU (1) | AU3960700A (en) |
CA (1) | CA2367899A1 (en) |
GB (1) | GB9906124D0 (en) |
MX (1) | MXPA01009385A (en) |
WO (1) | WO2000056733A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9914743D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
CA3138307A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9321162D0 (en) * | 1993-10-13 | 1993-12-01 | Boots Co Plc | Therapeutic agents |
GB9617727D0 (en) * | 1996-08-23 | 1996-10-02 | Knoll Ag | Process |
-
1999
- 1999-03-18 GB GBGB9906124.4A patent/GB9906124D0/en not_active Ceased
-
2000
- 2000-03-06 MX MXPA01009385A patent/MXPA01009385A/en unknown
- 2000-03-06 JP JP2000606594A patent/JP2002540110A/en not_active Withdrawn
- 2000-03-06 EP EP00918762A patent/EP1183257A1/en not_active Withdrawn
- 2000-03-06 WO PCT/EP2000/001934 patent/WO2000056733A1/en not_active Application Discontinuation
- 2000-03-06 CA CA002367899A patent/CA2367899A1/en not_active Abandoned
- 2000-03-06 CN CN00807525A patent/CN1353714A/en active Pending
- 2000-03-06 AU AU39607/00A patent/AU3960700A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000056733A1 (en) | 2000-09-28 |
MXPA01009385A (en) | 2004-03-19 |
AU3960700A (en) | 2000-10-09 |
CN1353714A (en) | 2002-06-12 |
GB9906124D0 (en) | 1999-05-12 |
EP1183257A1 (en) | 2002-03-06 |
JP2002540110A (en) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100353014B1 (en) | Pyrazolopyrimidinone derivatives for the treatment of impotence | |
US5580866A (en) | Therapeutic 1,4-thiazepines | |
EP0723546B1 (en) | 1,2,4 - TRIZOLO[1,5-a]PYRIMIDINE AND THEIR USE FOR TREATMENT OF NEUROLOGICAL DISORDERS | |
RU2136682C1 (en) | Imidazopyridines, method of their synthesis, pharmaceutical composition on said and method of pharmaceutical composition preparing | |
EP0820456B1 (en) | 1,2,4-triazolo 4,3-b]pyridazine derivatives and their use | |
US20160264535A1 (en) | Benzofurazan anti-amyloid compounds and methods | |
US5877175A (en) | Pharmaceutical compositions | |
JP4717210B2 (en) | 5-heterocyclylpyrazolo [4,3-d] pyrimidin-7-one for the treatment of male erectile dysfunction | |
EP0269755B1 (en) | DIBENZ b,e]OXEPIN DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME AS ACTIVE INGREDIENT | |
CA2367899A1 (en) | Triazolopyrimidinol compounds and salts thereof | |
CN115850289B (en) | Novel pranoprofen derivative, and pharmaceutical composition and application thereof | |
EP0573548B1 (en) | Neuroprotectant agents | |
AU6414599A (en) | Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and anfiinflammatory activity | |
AU680639C (en) | 1,4-benzothiazepines useful as neurological agents | |
CN109280028A (en) | Quinolines and its application in DPP-4 enzyme inhibitor | |
JPH0625184B2 (en) | Novel substituted benzothiazolinones, process for their production and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |